To include your compound in the COVID-19 Resource Center, submit it here.

IW001: Phase I started

ImmuneWorks began an open-label, U.S. Phase I trial to evaluate once-daily

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE